ACON: Aclarion Corp Consensus Target

Aclarion (ACON) is developing a cloud-based AI service for MRI analysis that scales efficiently via a subscription model. The company is supported by a cohesive team of IT specialists and spectroscopy experts. Business growth relies on the recognition of Nociscan algorithms by insurance companies, with the current metric standing at 7.76. This chart of the market value below illustrates the price action for this diagnostic software developer.

ACON Aclarion Inc Price Target Chart (04/28/2023 - 11/11/2026)

Analytical breakdowns for Aclarion Corp (ACON)

- stock value and consensus price forecast:

Stock Price aclarion.com|ACON - Analyst Consensus Forecast

- market capitalization information:

Market Valuation Aclarion Corp|ACON - Total Company Value

- book value of equity indicators:

Net Asset Value per Share Aclarion|ACON - Company Book Value|Capitalization to Book Value Ratio aclarion.com|ACON - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

ACON - Company Net Income|Expected Net Profit Aclarion|ACON - Price to Earnings Ratio|Market Cap to Projected Earnings Aclarion Inc|ACON - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Aclarion Corp|ACON - Operating profit EBITDA|Net earnings per share for the last four quarters Aclarion|ACON - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months aclarion.com|ACON - Net earnings per share growth this year|Expected earnings per share trend next year Aclarion

General company analysis:ACON aclarion.com

This indicator reflects an aggregated fair value assessment of the asset by calculating the gap between current quotes and the average yield expectations of investment banks. By analyzing the consensus target price, an investor determines the degree of undervaluation for Aclarion (ACON), which is currently supported by a technological breakthrough in autonomous AI analysis of MRI scans via the NociScan platform, eliminating the human factor in pain diagnostics.

Competing companies